Novavax COVID-19 vaccine
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Subunit |
| Clinical data | |
| Trade names | Covovax,[1] Nuvaxovid[2][3][4] |
| Other names | |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax,[1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations.[26]
Updated versions of the vaccine have been developed to provide coverage against the Omicron variant, with different formulas for 2023–2024 (containing a recombinant spike protein from lineage XBB.1.5)[27] and 2024–2025 (containing recombinant spike protein from lineage JN.1).[28]
- ^ a b "WHO issues emergency use listing to Novavax-Serum Institute's COVID-19 vaccine". Reuters. 17 December 2021. Archived from the original on 17 December 2021. Retrieved 17 December 2021.
- ^ a b c "Nuvaxovid APMDS". Therapeutic Goods Administration (TGA). 20 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
- ^ a b "Regulatory approval of COVID-19 vaccine Nuvaxovid". Medicines and Healthcare products Regulatory Agency (MHRA). 3 February 2022. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
- ^ a b Cite error: The named reference
Nuvaxovid EPARwas invoked but never defined (see the help page). - ^ "EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)" (Press release). European Medicines Agency (EMA). 3 February 2021. Archived from the original on 2 July 2021. Retrieved 30 June 2021.
- ^ "Novavax and Takeda Finalize License Agreement for Novavax' COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan" (Press release). GlobeNewswire. 26 February 2021. Archived from the original on 2 June 2021. Retrieved 29 May 2021.
- ^ "EMEA-002941-PIP01-20". European Medicines Agency (EMA). 16 March 2021. Archived from the original on 21 June 2021. Retrieved 29 June 2021.
- ^ "SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19". secondary. Aust Prescr. 45 (2): 62. April 2022. doi:10.18773/austprescr.2022.012. PMC 9081941. PMID 35592366. Archived from the original on 26 March 2022. Retrieved 14 May 2022.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
- ^ "Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - Oct 3, 2023". Novavax (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023.
- ^ a b "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 5 February 2022. Retrieved 5 February 2022.
- ^ a b "AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant". Therapeutic Goods Administration (TGA). 21 January 2022. Archived from the original on 24 March 2022. Retrieved 23 March 2022.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
- ^ "AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 27 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
- ^ "AusPAR: SARS-CoV-2 rS vaccine with Matrix-M1 adjuvant". Therapeutic Goods Administration (TGA). 24 June 2022. Archived from the original on 16 July 2022. Retrieved 17 July 2022.
- ^ "Novavax) (Biocelect Pty Ltd) Labelling Exemption 2022". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 19 March 2023. Retrieved 9 April 2023.
- ^ "Nuvaxovid". Australian Public Assessment Report (AusPAR). The Department of Health and Aged Care, Australian Government.
- ^ Novavax, Inc. (24 March 2022). "Product Monograph, NUVAXOVID ™, COVID-19 Vaccine (Recombinant protein, Adjuvanted)" (PDF). Archived (PDF) from the original on 29 May 2022. Retrieved 14 July 2022.
- ^ "Novavax Nuvaxovid COVID-19 vaccine". Health Canada. 17 February 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Nuvaxovid". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ^ "Nuvaxovid". Health Canada. 17 February 2022. Archived from the original on 1 June 2022. Retrieved 31 May 2022.
- ^ "Summary Basis of Decision (SBD) for Nuvaxovid XBB.1.5". Health Canada. 9 February 2024. Retrieved 24 February 2024.
- ^ "Nuvaxovid". U.S. Food and Drug Administration. 16 May 2025. Archived from the original on 19 May 2025. Retrieved 19 May 2025. This article incorporates text from this source, which is in the public domain.
- ^ "NUVAXOVID COVID-19 VACCINE, ADJUVANTED- nvx-cov2705 injection, suspension". DailyMed. 5 June 2025. Retrieved 6 July 2025.
- ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
- ^ Leo L (27 March 2021). "Hope to launch Covovax by September, says Serum Institute CEO". mint. Archived from the original on 13 May 2021. Retrieved 28 March 2021.
- ^ "FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants". U.S. Food and Drug Administration (FDA) (Press release). 3 October 2023. Archived from the original on 4 October 2023. Retrieved 4 October 2023. This article incorporates text from this source, which is in the public domain.
- ^ "Novavax COVID-19 Vaccine, Adjuvanted- nvx-cov2705 injection, suspension". DailyMed. 3 September 2024. Retrieved 16 September 2024.